In the previous quarter, the company issued new stock options to two executives, signed by the CEO. These options were recorded in the accounts at year-end and listed in the financial statements. However, before the financial statements were formally issued, the board had not given final approval and is not expected to approve them. Therefore, these options will be cancelled.

Given that such options are only valid with board approval, should the presentation and recording in the year-end accounts and notes to the financial statements be eliminated as if the options were never issued before year-end? Or must they be recorded first and then reversed in the first quarter?

Analysis of Accounting Principles

According to accounting standards, if a transaction does not meet all necessary conditions (such as board approval) at the balance sheet date, the related equity instrument should not be recognized. Since the options had not received board approval at year-end and approval is not expected, they do not meet the 'granted' condition at the balance sheet date. Therefore, when preparing the year-end financial statements, it should be treated as if the options were never issued, with no related records retained in the accounts and no disclosure required in the notes (unless other disclosure obligations exist).

If the company has already recorded them, a correction should be made before the statements are issued, i.e., reversing the original entry so that the year-end accounts reflect the true situation. This correction is an adjustment for subsequent events, not a new transaction in the first quarter, so no reversal entry should be made in the first quarter.

Internal Control Assessment: Does It Constitute a Material Weakness

The second part of the question asks: Does the fact that these options should not have been issued and the CEO signed them without board approval constitute a material weakness? Since the issue was discovered before the financial statements were issued and did not result in a material misstatement, is it unnecessary to disclose it in the report?

According to internal control guidelines, a material weakness is a deficiency in internal control that could result in a material misstatement in the financial statements not being prevented or detected in a timely manner. The CEO's unauthorized issuance of options indicates a failure in the company's authorization controls over option grants, which may constitute a control deficiency. However, whether it constitutes a 'material weakness' requires an assessment of the likelihood and potential impact of the deficiency.

Since the matter was discovered and corrected before the statements were issued and did not result in a material misstatement in the financial statements, it may not constitute a material weakness. However, the company still needs to assess the severity of the control deficiency. If the deficiency indicates a systemic gap in authorization controls, it may constitute a 'significant deficiency' that requires disclosure in management's internal control report. If it is an isolated event that has been promptly corrected and does not affect other controls, it may not need to be disclosed in the statements, but should be documented in internal audit files.

In summary, the company is advised to:

  • Reverse the option record in the year-end accounts, treating it as if never issued;
  • No disclosure of the options is required in the notes to the financial statements (unless other disclosure requirements apply);
  • Assess the nature of the authorization control deficiency. If it is an isolated event that has been corrected, it may not need to be disclosed as a material weakness, but relevant internal control processes should be strengthened.

The final treatment should follow the company's applicable accounting standards (such as IFRS or US GAAP) and internal control frameworks (such as COSO), and professional auditors should be consulted.